E. Swietlik (Cambridge, United Kingdom), M. Wilkins (London, United Kingdom)
Exhaled breath olfactory signature of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
S. Cohen-Kaminsky (Le Kremlin-Bicêtre, France), S. Sherbo (Haifa, Israel), Z. Wang (Haifa, Israel), E. Jutant (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France), B. Girerd (Le Kremlin-Bicêtre, France), E. Lau (Le Kremlin-Bicêtre, France), L. Becquemont (Le Kremlin-Bicêtre, France), Y. Broza (Haifa, Israel), H. Haick (Haifa, Israel), M. Humbert (Le Kremlin-Bicêtre, France)
|  |
Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH)
A. Galkin (San Diego, United States of America), R. Sitapara (San Diego, United States of America), B. Clemons (San Diego, United States of America), E. Garcia (San Diego, United States of America), M. Kennedy (San Diego, United States of America), L. Carter (San Diego, United States of America), D. Slee (San Diego, United States of America), L. Salter-Cid (San Diego, United States of America), L. Zisman (San Diego, United States of America)
|  |
GCN2 regulates BMP signaling: consequence for PVOD pathobiology and therapeutic management
G. Manaud (Le Kremlin-Bicêtressis-Robinson, France), M. Lambert (Le Kremlin-Bicêtressis-Robinson, France), B. Soilih (Le Kremlin-Bicêtresis-Robinson, France), B. Girerd (Le Kremlin-Bicêtre, France), F. Soubrier (Paris, France), J. Bignard (Paris, France), O. Claude (Paris, France), F. Lecerf (Le Kremlin Bicêtre, France), M. Florio (Thousand Oaks, United States of America), B. Sun (Thousand Oaks, United States of America), S. Nadaud (Paris, France), S. Verleden (Leuven, Belgium), S. Rémy (Nantes, France), I. Anegon (Nantes, France), O. Mercier (Le Plessis-Robinson, France), E. Fadel (Le Plessis-Robinson, France), G. Simmoneau (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France), F. Antigny (Le Kremlin-Bicêtre, France), F. Perros (Le Kremlin-Bicêtre, France)
| |
Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL)
A. Frost (Houston, United States of America), C. Zhao (South San Francisco, United States of America), H. Farber (Boston, United States of America), R. Benza (Pittsburgh, United States of America), M. Selej (South San Francisco, United States of America), G. Elliott (Murray, United States of America)
| |
Gut microbiota and pulmonary hypertension:a Mendelian randomization study
Y. Chen (Guangzhou, China), J. Liao (Guangzhou, China), T. Zhang (Guangzhou, China), C. Zhang (Guangzhou, China), K. Yang (Guangzhou, China), J. Wang (Guangzhou, China)
| |
Multi-Omics Analysis of the PDGF Response in Pulmonary Vascular Smooth Muscle Cells from Patients with Pulmonary Arterial Hypertension: Implication of the NMDAR
F. AKOUMIA (SAVIGNY-SUR-ORGE, France)
| |
SERCA2a gene therapy ameliorates pulmonary hypertension in a pig model: comparison of different delivery methods and therapeutic effect
O. Bikou (New York, United States of America), S. Tharakan (New York, United States of America), K. Yamada (New York, United States of America), T. Kariya (New York, United States of America), J. Aguero (New York, United States of America), K. Fish (New York, United States of America), K. Ishikawa (New York, United States of America)
| |
HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension
X. Sun (Amsterdam, Netherlands), E. Peters (Amsterdam, Netherlands), I. Schalij (Amsterdam, Netherlands), F. De Man (Amsterdam, Netherlands), M. Goumans (Leiden, Netherlands), K. Kurakula (Leiden, Netherlands), H. Bogaard (Amsterdam, Netherlands)
| |
Regulation of Type I cytokine receptors as a target for pulmonary arterial hypertension treatment?
E. Jutant (Le Kremlin-Bicêtre, France), L. Tu (Le Kremlin-Bicêtre, France), B. Le Vely (Le Kremlin-Bicêtre, France), R. Thuillet (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), C. Guignabert (Le Kremlin-Bicêtre, France), A. Huertas (Le Kremlin-Bicêtre, France)
| |
Loss of Bmp9 does not lead to spontaneous pulmonary hypertension, but attenuates vascular remodeling in experimental models
N. BERREBEH (Le Kremlin-Bicêtre, France), R. Thuillet (Le Kremlin-Bicêtre, France), L. Tu (Le Kremlin-Bicêtre, France), B. Le Vely (Le Kremlin-Bicêtre, France), A. Cumont (Le Kremlin-Bicêtre, France), I. Anegon (Nantes, France), A. Huertas (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), S. Bailly (Grenoble, France), C. Guignabert (Le Kremlin-Bicêtre, France)
| |
Role of c-Abelson in the loss of genome integrity in endothelial cells in pulmonary arterial hypertension
B. Le Vely (Le Kremlin-Bicêtre, France), N. Berrebeh (Le Kremlin-Bicêtre, France), C. Phan (Le Kremlin-Bicêtre, France), R. Thuillet (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), A. Huertas (Le Kremlin-Bicêtre, France), C. Guignabert (Le Kremlin-Bicêtre, France), L. Tu (Le Kremlin-Bicêtre, France)
| |
Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension
E. Moura (Coronado (S Mamede e S Romão), Portugal), C. Costa (Coronado (S Mamede e S Romão), Portugal), B. Igreja (Coronado (S Mamede e S Romão), Portugal), N. Pires (Coronado (S Mamede e S Romão), Portugal), V. Batalha (Coronado (S Mamede e S Romão), Portugal), M. Bonifacio (Coronado (S Mamede e S Romão), Portugal), P. Soares-Da-Silva (Porto, Portugal)
| |
SUR1/Kir6.2 potassium channel a new actor involved in pulmonary arterial hypertension
H. Le Ribeuz (Le Kremlin Bicetre, France), M. Lambert (Le Kremlin Bicetre, France), A. Boet (Le Kremlin Bicetre, France), D. Montani (Le Kremlin Bicetre, France), W. Chung (New York, United States of America), M. Humbert (Le Kremlin Bicetre, France), F. Antigny (Le Kremlin Bicetre, France)
| |
The modulatory effects of Nrf2 activators in a pulmonary arterial hypertension model
J. Li (Manchester, United Kingdom), J. Baker (Manchester, United Kingdom), C. Murray (Manchester, United Kingdom), N. Cooper (Manchester, United Kingdom), C. Lucas (Manchester, United Kingdom), D. Singh (Manchester, United Kingdom), S. Lea (Manchester, United Kingdom)
| |
Hemodynamic and histological progression in the Sugen-Hypoxia Rat Model
M. Corboz (Bridgewater, United States of America), S. Gagnon (Sherbrooke , Canada), A. Bouchard (Sherbrooke , Canada), C. Brodeur (Sherbrooke , Canada), C. Laurent (Sherbrooke , Canada), D. Salvail (Sherbrooke , Canada), D. Cipolla (Bridgewater, United States of America), W. Perkins (Bridgewater, United States of America), R. Chapman (Bridgewater, United States of America)
| |
Effects of Long Term Exogenous Apelin Application in Experimental Pulmonary Hypertension Model Created with Monocrotaline
O. OZTURK (Isparta, Turkey), R. Aslankoc (Isparta, Turkey), M. Saygin (Isparta, Turkey), Ö. Özmen (Burdur, Turkey), Y. Sirin (Burdur, Turkey)
| |
NGF induces pulmonary arterial hyperreactivity through connexin 43 increased expression
g. Cardouat (Bordeaux , France), M. Douard (Bordeaux , France), L. Roubenne (Bordeaux , France), Z. Kmecová (Bratislava, Slovakia), P. Robillard (Bordeaux , France), C. Guignabert (Paris, France), L. Tu (Paris, France), F. Delcambre (Bordeaux, France), R. Marthan (Bordeaux , France), B. Muller (Bordeaux , France), C. Guibert (Bordeaux , France), V. Freund-Michel (Bordeaux , France)
| |